Search form


Press Releases

Axcan Announces Conference Call and Web Cast for Second Quarter of Fiscal 2004 Results

Apr 22, 2004 - 12:00 ET

Axcan Announces Conference Call and Web Cast for Second Quarter of Fiscal 2004 Results 

MONT SAINT-HILAIRE, Quebec, April 22 - Axcan Pharma Inc.
("Axcan" or the "Company") today announced that it will report second quarter
of fiscal 2004 financial results on Thursday, May 6, 2004.

Axcan will host a conference call at 4:30 P.M. EST, on Thursday, May 6,
2004. Interested parties may also access the conference call by web cast at . The web cast will be archived for 90 days.

The telephone numbers to access the conference call are (800) 814-4859
(Canada and United States) or (416) 640-4127 (international). A replay of the
call will be available until May 13, 2004. The telephone number to access the
replay of the call is (416) 640-1917 code: 21043281.

Axcan is a leading specialty pharmaceutical company involved in the field
of gastroenterology. Axcan markets a broad line of prescription products sold
for the treatment of symptoms in a number of gastrointestinal diseases and
disorders such as inflammatory bowel disease, irritable bowel syndrome,
cholestatic liver diseases and complications related to cystic fibrosis.
Axcan's products are marketed by its own sales force in North America and
Europe. Its common shares are listed on the Toronto Stock Exchange under the
symbol "AXP" and on the NASDAQ National Market under the symbol "AXCA".

    "Safe Harbor" statement under the Private Securities Litigation Reform
    Act of 1995.

    To the extent any statements made in this release contain information
    that is not historical, these statements are essentially forward looking
    and are subject to risks and uncertainties, including the difficulty of
    predicting FDA approvals, acceptance and demand for new pharmaceutical
    products, the impact of competitive products and pricing, new product
    development and launch, reliance on key strategic alliances, availability
    of raw materials, the regulatory environment, fluctuations in operating
    results and other risks detailed from time to time in the company's
    filings with the Securities and Exchange Commission.

David W. Mims
Executive Vice President and 
Chief Operating Officer
Axcan Pharma Inc.
(205) 991-8085 ext. 223
Julie Thibodeau
Manager, Investor Relations
Axcan Pharma Inc.
(450) 467-5138 ext. 2062